Cargando…

Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease

The global pandemic of COVID-19 caused by SARS-CoV-2 continues to spread and poses serious threats to public health and economic stability throughout the world. Thus, to protect the global population, developing safe and effective vaccines is mandatory to control the spread of SARS-CoV-2 pandemic. S...

Descripción completa

Detalles Bibliográficos
Autor principal: Belete, Tafere Mulaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826065/
https://www.ncbi.nlm.nih.gov/pubmed/33500636
http://dx.doi.org/10.2147/IDR.S288877
_version_ 1783640453317394432
author Belete, Tafere Mulaw
author_facet Belete, Tafere Mulaw
author_sort Belete, Tafere Mulaw
collection PubMed
description The global pandemic of COVID-19 caused by SARS-CoV-2 continues to spread and poses serious threats to public health and economic stability throughout the world. Thus, to protect the global population, developing safe and effective vaccines is mandatory to control the spread of SARS-CoV-2 pandemic. Since genomic sequences of SARS-CoV-2 and SARS-CoV-1 have similarity and use the same receptor (ACE2), it is important to learn from the development of SARS-CoV-1 vaccines for the development of SARS-CoV-2 vaccines. Normally vaccine development takes 10–15 years but vaccine development against SARS-CoV2 is going on at a very fast pace resulting in almost breakthrough methods of vaccine development by several research institutions. The whole process of vaccine development including clinical trials gets shortened and may be fast tracked to 15–18 months. Global collaborations and increased research efforts among the scientific community have led to more than 214 candidate vaccines globally. The current review highlights the different approaches and technologies used around the world for the design and development of the vaccines and also focuses on the recent status of the SARS-CoV-2 vaccine candidates under development by various institutions to combat the world threat of COVID-19 pandemic.
format Online
Article
Text
id pubmed-7826065
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78260652021-01-25 Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease Belete, Tafere Mulaw Infect Drug Resist Review The global pandemic of COVID-19 caused by SARS-CoV-2 continues to spread and poses serious threats to public health and economic stability throughout the world. Thus, to protect the global population, developing safe and effective vaccines is mandatory to control the spread of SARS-CoV-2 pandemic. Since genomic sequences of SARS-CoV-2 and SARS-CoV-1 have similarity and use the same receptor (ACE2), it is important to learn from the development of SARS-CoV-1 vaccines for the development of SARS-CoV-2 vaccines. Normally vaccine development takes 10–15 years but vaccine development against SARS-CoV2 is going on at a very fast pace resulting in almost breakthrough methods of vaccine development by several research institutions. The whole process of vaccine development including clinical trials gets shortened and may be fast tracked to 15–18 months. Global collaborations and increased research efforts among the scientific community have led to more than 214 candidate vaccines globally. The current review highlights the different approaches and technologies used around the world for the design and development of the vaccines and also focuses on the recent status of the SARS-CoV-2 vaccine candidates under development by various institutions to combat the world threat of COVID-19 pandemic. Dove 2021-01-19 /pmc/articles/PMC7826065/ /pubmed/33500636 http://dx.doi.org/10.2147/IDR.S288877 Text en © 2021 Belete. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Belete, Tafere Mulaw
Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease
title Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease
title_full Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease
title_fullStr Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease
title_full_unstemmed Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease
title_short Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease
title_sort review on up-to-date status of candidate vaccines for covid-19 disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826065/
https://www.ncbi.nlm.nih.gov/pubmed/33500636
http://dx.doi.org/10.2147/IDR.S288877
work_keys_str_mv AT beletetaferemulaw reviewonuptodatestatusofcandidatevaccinesforcovid19disease